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Abstract
Background: High prevalence of musculoskeletal disorders in racehorses and its impact on horse welfare and
racing economics call for improved measures of injury diagnosis and prevention. Serum biomarkers of bone and
cartilage metabolism have previously shown promise in prediction of musculoskeletal injuries in horses. This study
aimed to re-evaluate usability of the predictive serum biomarkers identified in North American Thoroughbred
racehorses in a geographically distinct group of Polish Thoroughbreds.
Results: Serum concentrations of bone and cartilage biomarkers: osteocalcin, c-terminal telopeptide of type I
collagen, total glycosaminoglycans (GAG), chondroitin sulfate epitope and c-propeptide of type II procollagen (CPII)
were evaluated in the beginning and the next 3 months of one racing season in a cohort of twenty-six 2-year-old
Polish racehorses. Exit criteria were diagnosis of musculoskeletal injury, leading to > 5 days off training (n = 8), or
completion of 3 study months with no training interruptions (n = 18). Normalized results and matching archival
data from 35 2-year-old North American racehorses was used for logistic regression analysis to identify universal
predictors of injury. Mean GAG and CPII levels were lower in injured group comparing to control, which is
consistent with previous findings in racehorses. These biomarkers were also identified as predictors of injury in the
mixed population model. Population origin had no significant effect on predictive value of evaluated biomarkers
(Wald test p = 0.137). Decreased osteocalcin and increased c-terminal telopeptide of type I collagen levels in injured
horses comparing to controls were specific for Polish population and signalized disruption in bone turnover
homeostasis.
Conclusions: Changes in serum GAG and CPII in racehorses at risk of injury appear to be similar across distinct
populations while dynamics of serum bone marker is more population-specific.
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Background
Thoroughbred racehorses are enrolled in high-intensity
training in their second year of life, before termination
of skeletal growth [1]. Orthopaedic injuries are respon-
sible for nearly 70% of the lost training days in Thor-
oughbred racing, with 2-year-olds failing to train more
frequently and for longer time periods than older horses
[2–5]. In all age groups, musculoskeletal injuries ac-
quired during the high-intensity exercise are the major
cause of on-track deaths as well as long-term interrup-
tions in horse racing careers [2, 6–8].
Serious impact of stress injuries on horse welfare and
horse racing economics encouraged the search for an ef-
fective diagnostic tool that would allow early identifica-
tion of the individuals at risk. Biochemical serum
markers can be particularly useful in monitoring of large
groups of horses due to the quick and minimally inva-
sive sample collection process. Research in blood
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biomarkers of equine musculoskeletal disease has shown
promising results for diagnosis of congenital and ac-
quired disorders [9–18] and prediction of injuries com-
monly acquired by racehorses [19–21]. Those studies
evaluated products of bone and cartilage metabolism
such as pro- and telopeptides of type I and type II colla-
gen molecules, glycosaminoglycans, non-collagenous
bone protein and osteocalcin. Bone and cartilage bio-
markers evaluated in blood and synovial fluid can reflect
changes in skeletal turnover related to pathologies as
well as resulting from exercise-induced mechanical load
[1, 22–24]. Therefore, training program and environ-
ment can be relevant factors affecting bone and cartilage
metabolism in racehorses and should be accounted for
in interpretation of biomarker analysis results.
Although musculoskeletal disorders are identified glo-
bally as the major health issue in racing Thoroughbreds,
prevalence of specific injury types can vary between the
countries or even individual training yards [2, 4]. The
risk factors proposed as having impact on injury patterns
in racehorse populations include training regimen (dis-
tance and speed) and racetrack characteristics (shape,
length, surface condition) [4, 25–36]. Differences in
commonly used track surfaces and training logistics are
particularly evident between European and North
American racing systems. Turf is a typical surface for
European horse racetracks, while the large part of racing
in North America is performed on dirt. Horses compet-
ing in different geographical locations are more prone to
specific musculoskeletal pathologies which led to dis-
crimination of European and North American Thor-
oughbreds as separate subjects of equine sports
medicine [37, 38]. While these differences are widely
recognized and addressed by epidemiological studies, at-
tempts to include inter-population variability in equine
biomarker research are lacking. The purpose of this
study was: a) longitudinal evaluation of selected bone
and cartilage biomarkers in the group of Polish Thor-
oughbred racehorses in their first training season; b) as-
sessment of these biomarkers in a predictive model of
injury, universal for Polish and North American racing
Thoroughbreds. We hypothesized that different racing
environments would lead to an altered pattern of bio-
marker changes in the Polish population compared to
the results previously acquired in North American race-
horses. However, we expected that the ability of some
biomarkers to predict musculoskeletal injuries would
prove to be independent of the population origin.
Methods
Animals
This was a longitudinal prospective study that involved
28 2-year-old Polish Thoroughbred racehorses in their
first training season. According to the European
directive EU/2010/63 and local law regulating animal ex-
periments, there was no need for the approval of Ethical
Committee for the described procedures, as the sample
collections were performed as part of non-experimental
clinical veterinary practice consented by the trainers and
the owners of the horses. The study population was re-
cruited from horses stabled and trained in one racing fa-
cility in Poland in the beginning of one racing season.
Horses were trained and raced on turf track belonging
to the racing facility. Three different trainers participated
in the study with 12, 10 and 6 horses respectively.
Horses entering the study were free of lameness, did not
have history of musculoskeletal injury and did not show
abnormalities in routine hematological examination (red
blood cell count, hematocrit, total hemoglobin concen-
tration, total white blood cell count, differential white
blood cell count). Exit criteria were sustaining single
musculoskeletal injury (injured group) or completion of
three study months without showing clinical signs of in-
jury (control group). Additionally, information on horse
health was collected in the month following the last
sample collection to ensure that horses classified as con-
trol did not sustain injury immediately after the study
end, which may have affected analysis of the results. To
be included as injured, the horse had to manifest clinical
signs requiring veterinary attention and leading to loss
of > 5 consecutive training days according to recommen-
dation of a veterinary surgeon. Diagnosis was made by
equine veterinarians cooperating with the racing stable
and made available to the authors of the study. Injuries
resulting from accidents (e.g., kick, fall) were not in-
cluded in the study. All information regarding training
regimen and injuries was collected during the monthly
interview with horse trainers. Approximate training
schedules implemented during the study period are pre-
sented in supplementary material (Additional file 1).
Horses trained six days a week and each workout was
preceded by a 10-min warm-up and followed by a
30-min cool-down in horse walker.
Sample collection
Blood samples were collected in one-month intervals,
starting with the baseline sample at the beginning of the
study. Health and training information was acquired at
the time of blood sample collection as well as horses
were observed for cases of unreported lameness by re-
search veterinary clinician collecting the samples. A total
of four samples were collected from all horses over the
three-month study period. Sampling took place between
6:00 and 7:00 AM after feeding and before daily exercise.
Samples were collected by jugular venipuncture, using a
blood collection system1 with a 20-gauge needle. Sam-
ples were centrifuged (4380 g for 5 min), serum was sep-
arated, divided into 1 ml aliquots into 1,5 ml Eppendorf
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tubes (3–4 aliquots/horse) and stored frozen at − 20 °C
within 1 h of collection. After collection and during pro-
cessing all samples were stored on ice.
Biomarker analysis
The biomarker panel used in this study was selected
based on the results of previously published equine bio-
marker studies [11–23, 39]. Five biomarkers that were
demonstrated as useful in diagnosis and prognostication
of musculoskeletal disease were: a) marker of bone for-
mation, OC; b) markers of articular cartilage turnover,
GAG and CS846; c) marker of type II collagen synthesis,
CPII; d) marker of type I collagen breakdown, CTX I.
These biomarkers are products of extracellular matrix
metabolism in articular cartilage (CPII, GAG, CS846),
bone (CTX I, OC) and tendon (CTX I) and provide in-
formation on the overall status of musculoskeletal sys-
tem in the horse.
Biomarker analysis was undertaken at the Orthopaedic
Research Laboratory, Colorado State University. The
samples were transported from Poland on dry ice and
remained frozen until analysis. All assays used for bio-
marker analysis were previously validated for use with
equine serum [40, 41]. Osteocalcin level was measured
by commercial ELISA kits2 in undiluted serum samples.
Glycosaminoglycan concentration was analyzed by
dimethyl-methylene blue assay in undiluted samples
after papain digestion [42]. Chondroitin sulfate epitope
and CPII were measured using commercial ELISA kits3
in samples diluted 1:5 and CTX I level was established
with an ELISA4 in 1:4 dilution. All samples were ana-
lyzed in duplicates and measurements were repeated if
intra-assay coefficient of variation (CV) exceeded 15%.
The mean in-house intra-assay CV for respective test
was: 12,0% (OC), 6,7% (GAG), 5,0% (CS846), 6,7%
(CPII), 10,9% (CTX I).
Historical data
To re-evaluate the predictive value of bone and cartilage
markers of musculoskeletal injury across two geograph-
ically distinct populations of Thoroughbred racehorses,
we used the historical data from the study on North
American Thoroughbreds completed by one of the au-
thors [21]. Cases from the historical database were se-
lected to match the studied group of Polish racehorses
in terms of age, gender, sample collection time (stage of
the training season, time from the injury/exit period)
and biomarker selection. Selected group involved all
2-year-old racehorses for whom the complete dataset of
biomarker measurements was available at three consecu-
tive months leading up to the injury. Control dataset in-
volved three consecutive measurements from racehorses
that did not suffer injury in the racing season, obtained
in the similar part of the year as the injured group and
the Polish population (spring-summer). Therefore, we
ensured that all horses enrolled in the analysis were at
the similar stage of training during the season of inter-
est. Characterization of both populations is presented in
Table 1. This subset of archival data, including 2 year old
horses only, has never been analyzed separately before.
The recent study uses a different statistical approach for
evaluation of predictive value of biomarkers and does
not duplicate previously published information.
Statistical analysis
Statistical analysis was performed with a statistical and
graphing programs5,.6 A significance level of 0.05 was
applied in all analyses. First, serum concentration of
each biomarker was averaged over entire study period
and compared between the injured and the control
group. Data normality was assessed in all groups by
Shapiro-Wilk test. Depending on data distribution,
means were compared by unpaired t-test or
Mann-Whitney test. Next, two-way interaction for the
injured and the control group by time period was per-
formed using mixed model ANOVA, with time as
within-subject factor and injury as between-subject fac-
tor and post-hoc test with Bonferroni correction. Results
were presented as mean and standard deviation (SD).
To generate the predictive model, data from the recent
and the historical population was normalized and
expressed as ratio of the injury/exit sample (Month 0/
Month 3, Month 1/Month 3 and Month 2/Month 3 ra-
tio). Therefore, only three first time points were ana-
lyzed for each biomarker (as the Month 3 sample served
as normalization factor). Normalization of raw values of
Table 1 Characterization of recent and historical population
used in the multivariate predictive models of musculoskeletal
injury
Geographical
location
Poland United States (California)
2 year old 2 year old
Number of horses 26 35
Males 15 18
Females 11 17
Control 18 29
Males
Females
Injured 8 6
Males
Females
DMD 2 1
Joint injury 3 2
Bone fracture 2 2
Tendonitis 1 1
DMD dorsal metacarpal disease
Turlo et al. BMC Veterinary Research           (2019) 15:66 Page 3 of 8
biomarker concentrations was prerequisite for integra-
tion of both databases in one multivariate analysis. The
rationale for normalizing data to the last sample, which
led to its exclusion from the analysis, is that it would
not be useful for assessment of predictive ability of ex-
amined biomarkers, as it was collected at the time of in-
jury. The outcome variable was whether or not a horse
has been diagnosed with injury during 3 months in the
study. Multivariate logistic regression (LOGISTIC proce-
duref ) performed on the integrated database was used to
classify horses as injured or uninjured (with no regard to
the injury type) using separate normalized biomarker
levels at each time point. Population origin was entered
in the analysis as additional categorical variable. Vari-
ables were selected for inclusion using a backward elim-
ination approach. In this approach, the intercept-only
model was fit first and results of the Wald test for indi-
vidual effects were evaluated. The effects with p > 0.1
were removed from the model. Next, variables that met
the significance level for inclusion were offered to a lo-
gistic regression analysis for assessment of their per-
formance in prediction of injury risk. Effect estimates
obtained from logistic regression were expressed as odds
ratios (OR), and variability as 95% confidence interval
(CI).
Results
Out of 28 horses enrolled in the study, 2 horses left the
racetrack before completion of 3 study months due to
weak performance unrelated to lameness. Samples from
those horses were not included in the analysis. The final
population included 26 horses, 15 males and 11 females.
Eighteen horses completed the whole study period with-
out manifesting clinical injury, 6 horses were diagnosed
with musculoskeletal injury in the third month of the
study and 2 horses sustained injury shortly after the end
of the study. Due to the close time distance from the last
sample collection to injury recognition (one week), these
two horses were classified in analysis as injured. Distri-
bution of cases among the trainers was 4 out of 12, 3
out of 10 and 1 out of 6 racehorses in the respective
training stables. Injuries were defined as dorsal metacar-
pal disease (n = 2), acute distal limb fracture (n = 2), ten-
donitis (n = 1) and front fetlock joint injury (n = 3).
Table 1 shows injury distribution in each population.
Data in all compared groups showed normal distribu-
tion as evaluated by Shapiro-Wilk test (p > 0.05), except
of CS846 serum levels in the control group. Nonpara-
metric methods were used for analysis of that biomarker.
Looking at serum concentrations of biomarkers averaged
over all time points, the injured group demonstrated sig-
nificantly lower GAG, CPII and OC and higher CTX I
levels comparing to control. There was no significant
difference in CS846 level between study groups
(Table 2).
Time did not seem to affect mean biomarker levels in
the injured and the control group, with the exception of
CPII, where significantly higher concentrations were ob-
served at the baseline point (Fig. 1). Mean OC level in
the control group and CTX I in the injured group
tended to steadily decrease towards the exit/injury
period, although no significant differences were observed
(Fig. 2). Comparisons of mean biomarker levels between
the injured and the control group at respective time
points showed no significant difference for GAG, CS846
and CPII throughout the whole study period (Fig. 1). In
the injured group, level of OC was significantly lower
than in the control group in all samples except of the
endpoint, while CTX I level was significantly higher in
baseline, endpoint and Month 2 sample (Fig. 2). In
Month 1 sample, CTX I level in the control group ap-
proximated that of the injured group, before returning
back to baseline in the Month 2 and the endpoint
samples.
Sixty-one horses from the current and the historical
study were entered into logistic regression analysis, 14
injured and 47 uninjured (see Table 1). Backwards elim-
ination procedure selected CPII level in Month 1 sample
and GAG level in Month 2 sample as significant effects
for final multivariable logistic regression model (Table 3).
These results suggest that there is an association be-
tween increased CPII and decreased GAG level and risk
of sustaining musculoskeletal injury.
Discussion
According to the current guidelines of OARSI Bio-
marker Working Group, demonstrating a link between
biomarker and clinical outcome in more than one pro-
spective clinical study is fundamental for considering it
scientifically sound [43]. This study aimed to reassess us-
ability of the prognostic biomarkers of musculoskeletal
disease identified in the North American population of
Thoroughbred racehorses [21] in a geographically
Table 2 Comparison of average serum concentration of
biomarkers between control and injured group in Polish
racehorse population
Biomarker Serum concentration (mean ± SD) p value
Control group Injured group
GAG (mcg/mL) 47.29 ± 4.83 42.16 ± 3.34 0.012 *
CS846 (ng/mL) 335.8 ± 126.8 270.6 ± 95.62 0.207
CPII (ng/mL) 3633 ± 590.0 3070 ± 706.7 0.044 *
OC (ng/mL) 59.53 ± 10.07 43.92 ± 5.734 0.0004 ‡
CTX I (ng/mL) 0.4152 ± 0.13 0.6285 ± 0.08 0.0002 ‡
* Values differ significantly p < 0.05; ‡ values differ significantly p < 0.001. SD –
standard deviation
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distinct group of Polish racehorses. The results were ex-
pected to reveal how environmental differences may
affect biomarker performance as the injury predictor.
While direct comparisons of data from both studies
were not possible, trends in biomarker levels over time
and differences between control and injured group re-
ported in the current study will be contrasted with the
previous results from the North American population in
the following paragraphs.
The declining trend of OC and CTX I serum levels
over time in both control and injured groups (Fig. 2) in
the recent study may be interpreted as physiological,
age-related change previously described in maturing
Thoroughbreds [21, 44]. In the current study, signifi-
cantly lower OC, and higher CTX I levels were reported
in the injured racehorses comparing to the control
group. That difference was observed between both
values averaged over the whole study period and mean
values for the respective time points (Fig. 2). It suggests
that balance of bone synthesis and resorption in those
individuals was disrupted, leading to loss of bone mech-
anical resistance and subsequent stress injury. None of
these changes were reported in North American race-
horses [21], which supports our hypothesis that bio-
marker profiles of these two populations will differ to
some extent, presumably due to varying training envir-
onment. Epidemiological studies demonstrated before
high rate of skeletal injuries in horses racing on a turf
track surface [33, 34]. Indeed, bone injuries were the
major group of injuries observed in the Polish race-
horses analyzed in this study (Table 1). Although the ex-
amined sample cannot be considered representative for
population due to its small size, acute disruption in bone
turnover equilibrium in the injured horses trained on
Fig. 1 Mean ± SD serum concentration of biomarkers of cartilage
metabolism (CPII, GAG and CS846) over 3 months of race training in
2-year-old Thoroughbred horses that finally sustained
musculoskeletal injury (n = 8) and control horses (n = 18). * values
differ significantly p < 0.05
Fig. 2 Mean ± SD serum concentration of biomarkers of bone
formation (OC) and resorption (CTX I) over 3 months of race training
in 2-year-old Thoroughbred horses that finally sustained
musculoskeletal injury (n = 8) and control horses (n = 18). * values
differ significantly p < 0.05; † values differ significantly p < 0.01; ‡
values differ significantly p < 0.001
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turf track is an interesting observation that deserves a
follow-up study.
In cartilage biomarkers, average serum levels of CPII
and GAG were significantly lower in horses that were
going to suffer injury compared to control horses
(Table 2). The same observation was made in the North
American horses that finally sustained DMD (CPII,
GAG) or joint injury (GAG), two of the most common
injury types diagnosed in the Polish group in the current
study and previous studies on the same racehorse popu-
lation [45]. The lack of significant differences in GAG
and CPII levels between groups at the respective time
points could have resulted from relatively small size of
Polish sample comparing to the previous biomarker
study [21]. Glycosaminoglycan is a biomarker of cartil-
age proteoglycan turnover [46] whose increased serum
level can be observed at early stages of osteoarthritis but
also in the physiological response of cartilage to exercise
[13]. Lower average level of GAG in racehorses that
eventually sustained injury as compared to healthy
horses may suggest failed structural adaptation of cartil-
age to the increasing training load. This finding may be
supported by a lower average level of CPII in the injured
horses, the marker of cartilage-specific type II collagen
synthesis that has been shown to increase with exercise
[13]. CS846 epitope levels did not reach any significance
when analysed at the time of injury or as a part the pre-
dictive model, which appears to be in line with recent
clinical studies investigating that biomarker for diagnosis
of carpal osteochondral lesions [47].
The presented predictive model of injury was based on
normalized data derived from the current and the histor-
ical study (Table 1). To determine if population origin
would affect results of logistic regression analysis, it has
been entered into the procedure as an additional categor-
ical variable. However, it was eliminated at the initial stage
of the analysis as having no individual effect. That sug-
gested that relation between serum biomarkers and the
clinical outcome (presence/absence of injury) is universal
across populations and justified using merged databases in
the predictive model. This analysis did not reproduce the
statistical approach used in the historical study, where all
biomarker outcomes were tested together using the sup-
port vector machine model. Instead, we aimed to evaluate
performance of individual biomarkers at the respective
time points in order to determine the most accurate single
predictors of injury. Selecting key predictors out of a bio-
marker panel is essential for their further application in
research and practice, as it substantially reduces costs and
time of sample analysis. Interestingly, only GAG and CPII,
evaluated within two months before the injury were quali-
fied into the model. When compared to the bone markers,
GAG has formerly shown the fastest reaction and the
highest clinical correlation for detection of experimentally
induced equine osteoarthritis [46] and fastest reaction to
physiological exercise in healthy horses [13]. Although
joint disorders represented only a fourth of all injuries in-
cluded in the analysis (Table 1), it is possible that articular
cartilage metabolism reflects a general response of the
skeleton to mechanical overload and products of this reac-
tion can be detected in blood sooner than biomarkers dir-
ectly related to the structure affected by clinical pathology.
Short reaction time of GAG and CPII may have also
contributed to the fact that their predictive value was
demonstrated at 1 (GAG) and 2 (CPII) months before
injury. In the studies using serum bone markers for in-
jury risk assessment, the average time between sample
analysis and injury manifestation was 6 months [19, 20].
Using that time interval, marker of bone resorption,
ICTP, was demonstrated to be useful for identification of
horses at risk of developing dorsal metacarpal disease
[20]. In a longitudinal study of the North American
racehorse population, significant changes in OC and
CTX I serum levels were observed at 4 to 7 months
pre-injury when compared to both injury levels and the
control group. Therefore, the time period covered by the
current study might have been too short to capture rele-
vant changes in bone marker concentrations. However,
presented results suggest that biomarkers of cartilage
metabolism may be more useful for detection of race-
horses currently at risk of suffering musculoskeletal in-
jury, which could be of practical importance if regular
monitoring of GAG and CPII during racing season was
performed. CPII and GAG level changes have been pre-
viously demonstrated to correlate with imaging and
histopathological outcomes in diagnosis and severity
classification of equine osteoarthritis [48, 49], further
confirming their relevance as biomarkers of joint injury
in that species.
One of the potential limitations of the study was appli-
cation of immunoenzymatic assays for biomarker level
measurement that suffered of relatively high intra-assay
Table 3 Results of the logistic regression analysis for samples that demonstrated significant effects in backwards elimination analysis
(Wald Chi-Square p-value< 0.1)
Biomarker Time
point
Wald Chi-Square Test Odds Ratio Estimates
Wald Chi-Square p-value Point Estimate 95% Interval Limits
CPII Month 1 3.0435 0.08 1.72 0.94 3.17
GAG Month 2 5.1169 0.02 0.27 0.09 0.84
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imprecisions (10,9% in CTX I and 12% in OC ELISA).
Due to the comparative nature of the study, we chose to
use the same methods that have been previously applied
in the North American population. However, further im-
plementation of serum biomarkers in equine medicine
could benefit from more precise and preferably fully au-
tomated analytic methods.
Although serum biomarkers show promise as a poten-
tial screening tool for identification of horses at risk of
developing injury, further examination with well recog-
nised diagnostic methods is necessary in order to deter-
mine specific pathology type and location. Varied results
in bone marker dynamics between distinct racehorse
populations suggest that, as an indicator of bone metab-
olism, serum biochemical marker data should be used in
conjunction with clinical examination and diagnostic im-
aging for more meaningful results.
Conclusions
This study shows that racehorses in European training
system, represented by Polish population sample, might
be more prone to disruption of bone turnover homeo-
stasis that is reflected by differences in bone marker
serum levels. Environmental factors, particularly training
track surface, are proposed as an underlying cause of
identified difference in bone metabolism between North
American and Polish racehorses. Conversely, cartilage
markers appear to show similar dynamics in injured and
healthy racehorses regardless of population origin and
turn out to be more accurate predictors of approaching
injury.
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